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Abstract
Background: The incidence of young coronary heart disease (CHD, ≤45 years) in China is increasing. Secondary
prevention to counter this trend is an important contemporary public health issure.
Methods: A total of 5288 patients (≤45 years) diagnosed with CHD and hospitalized at the Chinese PLA General
Hospital and Anzhen Hospital, both in Beijing, were enrolled after satisfying the inclusion criteria.
Results: Young CHD patients increased in number from 2010 to 2014, especially men. Among the studied patients,
there was no significant change over those years in blood pressure, but heart rate increased significantly (P < 0.05)
and body mass index showed a rising trend (P > 0.05). The incidence of hypertension increased from 40.7 to 47.5%,
diabetes from 20.3 to 26.1%, and hyperlipidemia from 27.3 to 35.7% (P < 0.05). However, the incidences of smoking
and drinking both trended downward (P < 0.05). The levels of total cholesterol and triglycerides also showed a
downward trend (P < 0.05), as did levels of low-density lipoprotein, but not to the point of statistical significance
(P > 0.05). Mortality during hospitalization decreased significantly from 2010 to 2014 (P < 0.05), but there was no
significant improvement in the incidences of cardiac death and major adverse cardiovascular events (MACE) after
1-year follow-up (P > 0.05).
Conclusions: Over the 5 years studied, the overall incidence of cardiac death and MACE for young CHD patients
(≤45 years) has shown little improvement. Secondary prevention of young CHD, and its risk factors, as well as
appropriate courses of medical treatment must be further elucidated.
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Background
As economy and standard of living improve, the inci-
dence of coronary heart disease (CHD) rises [1]. This is
a major public health concern, as the overall mortality
from acute myocardial infarction (AMI) also increases.
The results of the China Patient-centered Evaluation
Assessment of Cardiac Events (ChinaPEACE) showed
that, from 2001 to 2011, the hospitalization rate for
ST-segment elevation myocardial infarction (STEMI)
increased each year [2]. According to Chinese Ministry
of Health epidemiological survey data, the number of
people who die from coronary heart disease each year
in China is estimated at more than 1 million. Further-
more, the number of deaths of men aged 35–55 has in-
creased rapidly [1]. Men aged <55 years and women
<65 years with CHD are considered to have premature
CHD [3]. With changing standards of living, dietary
habits, modes of work, exercise levels, and genetic fac-
tors, the onset age for CHD has gradually decreased.
Meanwhile, medical costs for young CHD patients have
increased considerably. This study analyzed the clinical
characteristics, risk factors, medical therapies, and
prognoses of young (≤45 years) CHD patients hospital-
ized in two facilities in Beijing between 2010 and 2014.
This study aims to provide further clinical data regard-
ing secondary prevention and treatment of CHD.
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From January 2010 to December 2014, 5288 young
(≤45 years) CHD patients were enrolled from the cardiac
centers of Chinese PLA General Hospital and Anzhen
Hospital, both in Beijing. The study protocol was ap-
proved by the Chinese PLA General Hospital and
Anzhen Hospital Review Boards, and both informed
consent and consent for publication were obtained from
all participants.
Inclusion criteria were: hospitalized in cardiac center
during an established period; underwent coronary
angiography; in accordance with the 1979 World
Health Organization (WHO) standard, stenosis of left
main artery ≥30%, or one or more of the left anterior
descending branch (LAD), left circumflex branch
(LCx), or right coronary artery (RCA) ≥50%;
diagnosed with CHD.
Exclusion criteria were: severe cardiomyopathy;
rheumatic heart disease; congenital heart disease;
severe congenital heart disease; malignant tumor;
use of oral contraceptive pill or currently pregnant.
Clinical data collection
All data were derived from the clinical data of the hospi-
talized patients. Risk factors analyzed included age, sex,
smoking, drinking, hypertension, hyperlipidemia, dia-
betes, and family history of CHD.
Laboratory data were collected upon admission to the
hospital, including levels of total cholesterol, triglycer-
ides, low-density lipoprotein (LDL), high-density lipo-
protein (HDL), hemoglobin, N-terminal pro-B-type
natriuretic peptide (NT-proBNP), serum creatinine,
troponin-T, creatine kinase-MB, urea nitrogen, and uric
acid. Echocardiographic parameters were assessed by
transthoracic echocardiography using the Teichholz
method prior to coronary angiography. Parameters ana-
lyzed included thickness of the interventricular septum,
left ventricular end-diastolic inner diameter, and left
ventricular ejection fraction.
All medical treatments during hospitalization were re-
corded, including aspirin, clopidogrel, statin, ticagrelor,
ACEI/ARB, β-blockers, nitrates, diuretics and digoxin.
Follow-up
All subjects were followed up for 1 year after their first
hospitalization. In the hospital, major adverse events
recorded included cardiogenic shock, major bleeding,
atrioventricular block (AVB), ventricular tachyarrhyth-
mia (VT), ventricular fibrillation (VF) and thrombosis.
After hospital discharge, major adverse events were
defined, including acute myocardial infarction (MI),
cardiac death, re-percutaneous coronary intervention
(re-PCI), re-coronary artery bypass grafting (re-CABG),
and stroke.
Definition
The primary endpoints were death and complications dur-
ing hospitalization. Complications during hospitalization
included cardiogenic shock, VT or VF requiring anti-
arrhythmic drugs or defibrillation, AVB requiring tempor-
ary cardiac pacemaker insertion, and major bleeding. The
thrombolysis in myocardial Infarction (TIMI) bleeding
criteria is used in this article [4]. Major bleeding was
defined as including any intracranial bleeding (exclud-
ing microhemorrhages <10 mm evident only on
gradient-echo magnetic resonance imaging), or clinic-
ally overt signs of hemorrhage associated with a drop
in hemoglobin of ≥5 g/dL, or fatal bleeding (directly re-
sults in death within 7 days). The secondary endpoint
was any major adverse cardiovascular events (MACE)
during the follow-up period, including cardiac death,
MI stroke, and emergency or elective repeat revascular-
ization. Cardiac death was defined as mortality not
resulting from noncardiac disease. If two or more com-
plications occurred in a single patient, each complica-
tion type was recorded. After discharge, any MACEs
during the follow-up period were recorded.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences software (SPSS, version
18.0). Continuous variables with normal distributions
were expressed as mean ± standard deviation, and com-
pared using one-way analysis of variance. Categorical
variables were compared using the chi-square test where
appropriate. MACE was estimated by the unadjusted
Kaplan–Meier method in the five groups from 2010 to
2014.
Results
Trends of clinical baseline data in young CHD patients
From 2010 to 2014, the average onset age of CHD young
patients demonstrated no significant change. The rates
of unstable angina and ST-segment elevation MI
(STEMI) increased, while non-ST-segment elevation MI
(NSTEMI) trended downward (see Table 1, Fig. 1).
There was no significant change in mean blood pressure
during hospitalization, but both heart rate and body
mass index (BMI) slightly increased (72.8 ± 11.8 bpm vs.
74.3 ± 12.7 bpm; 27.9 ± 3.1 vs. 28.1 ± 3.1; P < 0.05,
Table 1). The rates of various comorbidities, including
hypertension, diabetes, and hyperlipidemia, presented
upward trends over the 5 years, while smoking and alco-
hol consumption declined (Table 1). There were no dif-
ferences among patients who from geographically
different regions such cities or rural areas (P > 0.05).
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However, the proportion of those with high academic
achievement trended upward (P < 0.01). The young CHD
patients among all hospitalized patients, and such pa-
tients in the cardiac clinic among all patients in the car-
diac clinic, trended significantly upward (5.4 to 7.2, and
1.2 to 1.7%, respectively, P < 0.01).
Laboratory analysis and echocardiography
From 2010 to 2014, total cholesterol (4.54 ± 1.26 to 4.35
± 1.26) and triglyceride levels (3.12 ± 6.26 to 2.49 ± 6.83)
decreased (P < 0.05, Table 2). LDL cholesterol decreased
slightly, without statistical significance (P > 0.05), and
HDL cholesterol showed a significant decline (P < 0.05).












Age 40.4 ± 4.2 40.6 ± 4.1 40.7 ± 4.2 40.8 ± 4.2 40.8 ± 4.2 NS
Male (%) 766 (91.2) 876 (94.2) 983 (94.1) 1146 (92.3) 1184 (93.4) NS
SBP (mmHg) 123.9 ± 16.9 124.8 ± 16.9 123.9 ± 14.9 123.7 ± 15.3 123.5 ± 15.5 NS
DBP (mmHg) 78.2 ± 12.4 77.9 ± 12.1 77.0 ± 11.2 77.9 ± 11.4 77.6 ± 11.9 NS
HR 72.8 ± 11.8 72.4 ± 11.7 72.1 ± 11.2 74.3 ± 12.7 72.0 ± 11.0 0.000
BMI 27.9 ± 3.1 27.9 ± 3.2 27.7 ± 3.2 28.1 ± 3.1 27.6 ± 3.4 0.002
Risk factor
Hypertension (%) 342 (40.7) 379 (40.7) 496 (47.5) 498 (40.1) 529 (41.7) 0.005
Diabetes (%) 171 (20.3) 182 (19.6) 238 (22.7) 324 (26.1) 284 (22.4) 0.006
Hyperlipidemia (%) 230 (27.3) 244 (26.2) 371 (35.5) 362 (29.1) 453 (35.7) 0.000
Smoke (%) 502 (59.7) 572 (61.5) 646 (61.8) 710 (57.2) 728 (57.4) 0.020
Alcohol use (%) 210 (25.0) 255 (27.4) 325 (31.1) 323 (26.0) 317 (25.0) 0.014
Geographical differences
City area (%) 543 (67.5) 605 (65.1) 651 (65.2) 857 (69.1) 843 (66.5) NS
Scholarship 0.000
High (%) 436 (51.9) 466 (50.1) 594 (56.8) 735 (59.2) 744 (58.7)
Middle (%) 269 (32.0) 369 (39.7) 331 (31.7) 376 (30.3) 384 (30.3)
Low (%) 99 (11.8) 95 (10.2) 120 (11.5) 130 (10.5) 140 (11.0)
Diagnosis 0.000
SA 24 (2.8) 21 (2.2) 18 (1.7) 27 (2.1) 13 (1.0) 0.024
UA 394 (46.9) 505 (54.3) 566 (54.1) 706 (56.8) 723 (57.0) 0.003
NSTEMI 325 (38.7) 350 (37.6) 340 (32.5) 389 (31.3) 364 (28.7) 0.000
STEMI 52 (6.2) 41 (4.4) 104 (9.9) 99 (7.9) 151 (11.9) 0.000
ICM 9 (1.1) 13 (1.4) 17 (1.6) 20 (1.6) 17 (1.3) NS
Proportion of young CAD the total hospitalized patients (%) 5.4 5.8 5.7 6.9 7.2 0.000
Proportion of young CAD in the total Cardiac clinic (%) 2147 (1.2) 2085 (1.1) 2283 (1.2) 3279 (1.5) 3732 (1.7) 0.000
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BMI body mass index, SA stable angina, UA unstable angina, NSTEMI non-ST-
segment myocardial infarction, STEMI ST-segment elevation myocardial infarction, ICM ischemic cardiomyopathy, NS not significant
Fig. 1 Composition changes of coronary heart disease during the past 5 years from 2010 to 2014. 1: stable angina; 2: unstable angina; 3: non-ST
segment elevation myocardial infarction (NSTEMI); 4: ST segment elevation myocardial infarction (STEMI); 5: Ischemic cardiomyopathy. The rate of
stable angina pectoris and STEMI increased, while the NSTEMI decreased (P < 0.05)
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Blood glucose levels and glycosylated hemoglobin
showed no significant change (P > 0.05). The C-reactive
protein (CRP) presented downward trends from 2010 to
2014 (5.22 ± 1.13 to 3.38 ± 0.98; P < 0.01). Left ventricu-
lar end diastolic diameter and ventricular septum thick-
ness decreased (P < 0.05), while the ejection fraction had
no significant change.
Analysis of coronary artery lesion
Analysis of coronary angiography in young CHD pa-
tients frequently showed single vessel lesions, specifically
of the LAD, RCA, LCx, and left main artery. From 2010
to 2014, there were no significant changes in the com-
position of these lesions, except that the proportion of
left main artery lesions slightly increased (P < 0.05,
Table 3). In accordance with ACC/AHA classification of
coronary heart disease, our statistical analysis showed a
decreasing trend of A lesions, and an increasing trend of
C lesions. There was no significant change in TIMI flow
classification.
Medical treatment
Regarding anti-platelet treatment, the use of aspirin
increased from 87.3 to 96.7% over the 5 years, clopido-
grel use had a slight increase, and ticagrelor use in-
creased from 3.6 to 5.1% (P < 0.05, Fig. 2). Use of
statins also increased: from 69.1 in 2010, to 84.7 in
2012, to 82.1% in 2014 (P < 0.05). Use ofβ-blockers
was around 75% with no significant change. ACEI/
ARB also increased: from 35.1% in 2010, to 49.8% in













TC (mmol/L) 4.54 ± 1.26 4.48 ± 1.16 4.44 ± 1.35 4.42 ± 1.19 4.35 ± 1.26 0.020
TG (mmol/L) 3.12 ± 6.26 2.23 ± 1.51 2.28 ± 1.88 2.31 ± 1.89 2.49 ± 6.83 0.026
LDL (mmol/L) 3.21 ± 8.39 2.26 ± 0.96 2.75 ± 1.09 2.74 ± 1.01 2.77 ± 3.26 NS
HDL (mmol/L) 0.99 ± 0.22 0.94 ± 0.23 0.91 ± 0.21 0.89 ± 0.21 0.89 ± 0.20 0.000
Creatinine (mg/dL) 82.59 ± 34.06 78.41 ± 16.91 78.83 ± 47.32 77.85 ± 45.99 77.79 ± 18.38 0.030
BUN (mmol/L) 7.61 ± 4.85 7.29 ± 4.55 7.66 ± 5.17 7.51 ± 4.54 7.18 ± 4.53 NS
UA (μmol/L) 372.1 ± 111.2 355.5 ± 88.9 359.9 ± 91.3 367.9 ± 93.4 380.4 ± 91.9 0.000
ALT (U/L) 50.2 ± 48.3 45.4 ± 35.2 48.6 ± 43.1 46.8 ± 41.4 48.1 ± 42.0 NS
AST (U/L) 62.3 ± 92.7 56.7 ± 89.5 52.2 ± 77.2 51.2 ± 74.3 53.1 ± 77.4 NS
CK (U/L) 386.9 ± 875.3 368.3 ± 894.6 314.4 ± 737.5 336.8 ± 718.7 377.7 ± 928.1 NS
CKMB (ng/ml) 33.7 ± 76.1 29.4 ± 82.1 20.8 ± 60.5 26.0 ± 138.1 29.5 ± 141.3 NS
cTnT (ng/ml) 1.94 ± 1.43 1.82 ± 1.31 1.87 ± 1.53 1.97 ± 2.23 1.95 ± 1.97 NS
NT-proBNP (pg/ml) 657.0 ± 3973.8 385.6 ± 1348.7 372.8 ± 1638.5 206.8 ± 572.4 197.0 ± 561.7 0.000
Glucose (mmol/L) 6.73 ± 2.89 6.45 ± 2.51 6.57 ± 2.71 6.67 ± 2.68 6.56 ± 2.88 NS
HbA1c (%) 6.86 ± 1.76 6.64 ± 1.72 6.71 ± 1.71 6.16 ± 1.70 6.36 ± 1.63 NS
CRP (mg/dl) 5.22 ± 1.13 4.28 ± 1.28 4.43 ± 1.56 3.54 ± 1.25 3.38 ± 0.98 0.000
Hematologic
Hemoglobin (g/L) 147.4 ± 16.2 147.5 ± 15.3 146.2 ± 15.6 146.8 ± 16.0 147.6 ± 15.0 NS
Red cell count (10*12/L) 5.90 ± 1.89 5.91 ± 1.92 6.00 ± 1.91 6.15 ± 1.94 6.09 ± 1.99 0.017
White cell count (10*9/L) 9.20 ± 3.69 8.57 ± 2.99 8.41 ± 3.08 8.59 ± 3.34 8.74 ± 3.36 0.005
Platelet count 230.9 ± 72.7 228.8 ± 5.96 225.6 ± 58.8 233.8 ± 58.2 236.1 ± 64.2 NS
RDW (%) 12.96 ± 0.69 13.03 ± 0.62 12.80 ± 0.71 12.71 ± 0.79 12.91 ± 1.28 0.018
Echocardiography
LVDd (mm) 50.28 ± 5.38 49.64 ± 5.27 49.87 ± 5.84 49.92 ± 5.71 49.42 ± 5.44 0.028
IVST (mm) 10.07 ± 1.53 10.21 ± 1.51 10.13 ± 1.59 10.32 ± 1.58 10.05 ± 1.60 0.002
EF (%) 59.3 ± 9.2 59.8 ± 8.9 59.8 ± 9.5 59.8 ± 9.1 59.8 ± 9.0 NS
Abbreviations: TC total cholesterol, TG triglyeride, LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, Cr creatinine, BUN blood urea
nitrogen, UA uric acid, ALT alanine aminotransferase, AST Aspartate transaminase, CK creatine kinase, CKMB creatine kinase MB isoenzyme, cTnT cardiac Troponin T,
NT-proBNP N-terminal pro-B-type natriuretic peptide, HbA1c hemoglobin A1c, LVDd left ventricular end-diastolic dimension, IVST interventricular septal thickness,
EF ejection fraction
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2012, to 42.5% in 2014 (P < 0.05). Conversely, use of
nitrates decreased slightly, from 67.1 to 58.4% (P <
0.05). Use of other medical treatments, such as cal-
cium channel blockers (CCB), diuretics, and digoxin,
ranged around lower levels.
Events in hospital and follow-up
The rates of death (from 1.8 to 0.6%) and cardiac shock
(from 2.4 to 0.4%) in the hospitals decreased (P < 0.05,
Table 4), while the rates of AVB, VT, VF, and major
bleeding had no significant change. During the 1-year












Involved vessel number (%)
1 Branch
LAD (%) 256 (31.8) 320 (34.4) 368 (35.2) 408 (32.9) 384 (30.3) NS
LCx (%) 54 (6.7) 56 (6.0) 59 (5.6) 70 (5.6) 85 (6.7) NS
RCA (%) 85 (10.5) 100 (10.7) 115 (11.0) 143 (11.5) 134 (10.6) NS
2 branch (%) 235 (29.2) 292 (31.4) 288 (27.6) 365 (29.4) 387 (30.5) NS
3 branch (%) 160 (19.9) 157 (16.9) 211 (20.2) 241 (19.4) 268 (21.1) NS
LM (%) 14 (1.7) 5 (0.5) 4 (0.38) 14 (1.1) 10 (0.8) 0.018
ACC / AHA classification
A (%) 455 (56.6) 542 (58.3) 597 (57.1) 672 (54.1) 654 (51.6) 0.011
B1 (%) 95 (11.8) 103 (11.1) 129 (12.3) 149 (12.2) 133 (10.5) NS
B2 (%) 112 (13.9) 144 (15.5) 148 (14.2) 202 (16.3) 225 (17.7) NS
C (%) 142 (17.7) 141 (15.1) 171 (16.4) 218 (17.6) 256 (20.2) 0.029
TIMI flow (%)
TIMI 0 218 (27.1) 223 (24.0) 266 (25.5) 347 (28.0) 368 (29.0) NS
TIMI 1 2 (0.2) 12 (1.3) 3 (0.3) 4 (0.3) 6 (0.5) 0.007
TIMI 2 16 (2.0) 13 (1.4) 6 (0.6) 22 (1.8) 14 (1.1) NS
TIMI 3 568 (70.6) 682 (73.3) 770 (73.7) 868 (69.9) 880 (69.4) NS
Abbreviations: LAD left anterior descending artery, LCx left circumflex, RCA right coronary artery, NS not significant
Fig. 2 Change of medical use during hospitalization in2010–2014. Usage of aspirin, clopidogrel, ticagrelor, statins, and ß-blockers increased
overall (P < 0.05)
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follow-up, incidences of cardiac death, MI, PCI, CABG,
and stroke did not significantly change, nor did total
MACE events.
Discussion
The prevalence of cardiovascular disease in China is in-
creasing, an estimated 2.9 billion people with cardiovas-
cular disease in China [1], 2.7 billion people with
hypertension, 7 million with stroke, 2.5 million with MI,
and 4.5 million with heart failure. Li et al. reported that
during the past decade in China, hospital admissions for
STEMI have risen; in these patients, comorbidities and
the intensity of testing and treatment have also increased
[2]. Quality of care has improved for some treatments,
but vital gaps persist, and in the hospital, mortality has
not decreased. National efforts are needed to improve
care and outcomes of STEMI patients in China. Prema-
ture coronary heart disease is defined as men with onset
age <55 years, and women with onset age <65 years. The
present study showed that from 2010 to 2014 in China,
the proportion of young CHD patients in the depart-
ment of cardiology, as well as the proportion of young
CHD outpatient in the total outpatient cardiac clinic de-
partment trended upward, which may be partly associ-
ated with the rising incidence of young patients. With
changing lifestyles, diets, modes of working, and genetic
factors, the onset age of CHD has gradually gone down,
as young CHD patients with onset age <45 gradually in-
crease. The present study found that BMI of young
CHD patients had an increasing trend; BMI was 27.6 at
the upper limit, and the proportion of young obese
people was greater [5]. Moreover, incidence of CHD risk
factors, including hypertension, diabetes, and hyperlipid-
emia, increased. The proportion of smoking among
young people has declined, but the overall proportion
maintains a high ratio. Therefore, life-style changes, re-
habilitation exercise, weight control, stopping smoking,
and reducing hypertension, diabetes, and hyperlipidemia,
are all key objectives for secondary prevention of young
CHD.
The present study found that from 2010 to 2014, the
number of young CHD patients has shown an upward
trend, especiallyamong men. The rates of unstable an-
gina and STEMI increased significantly, consistent with
the ChinaPEACE results, while NSTEMI decreased.
Further analysis and comparison showed that the aver-
age blood pressure of young CHD patients during
hospitalization did not change significantly.
Previous studies [6] have shown that heart rate control
was associated with angina symptoms and prognosis.
This study showed that average heart rate remains high
during hospitalization, with an average of ≥72 bmp. The
use of ß-blockers increased over this 5-year period, but
overall use was <80%. The incidence of hypertension,
diabetes mellitus, and hyperlipidemia also rose. A report
on cardiovascular disease in China in 2014 showed that
the prevalence of hypertension had significantly in-
creased [1]. In 2002, a survey showed that 18% of people
in China aged >18 years had hypertension. Those with
hypertension had increased to 270 million as of 2014 [1].
In the present study, the prevalence of hypertension in
young CHD patients from 2010 to 2014 increased from
40.7 to 47.5%, with a slight downward trend. Diabetes is
also an important risk factor in cardiovascular disease
Table 4 In- and out-hospital outcomes from 2010 to 2014
2010 2011 2012 2013 2014 P
In-hospital outcome (n = 804) (n = 930) (n = 1045) (n = 1241) (n = 1268)
Death (%) 15 (1.8) 10 (1.1) 3 (0.3) 2 (0.2) 7 (0.6) 0.000
Complications (%)
Cardiogenic shock 17 (2.1) 19 (2.0) 4 (0.4) 8 (0.6) 5 (0.4) 0.000
Major bleeding 8 (1.0) 7 (0.8) 12 (1.1) 10 (0.8) 12 (0.9) NS
AV block 2 (0.2) 1 (0.1) 2 (0.2) 3 (0.2) - NS
VT and/or VF 22 (2.7) 25 (2.7) 22 (21.1) 21 (16.9) 23 (18.1) NS
Thrombosis 2 (0.2) 4 (0.4) 3 (0.3) 7 (0.6) 7 (0.6) NS
Out-hospital outcome N = 738 N = 840 N = 1017 N = 1216 N = 1257
MACE (%) 18 (2.4) 18 (2.1) 22 (2.2) 17 (1.4) 20 (1.6) NS
Cardiac death 1 (0.1) - 1 (0.1) 3 (0.2) 1 (0.1) NS
MI 10 (1.3) 14 (1.7) 14 (1.4) 13 (1.1) 16 (1.3) NS
Re-PCI 17 (2.3) 18 (2.1) 22 (2.2) 17 (1.4) 19 (1.5) NS
CABG 1 (0.1) - - - 1 (0.1) NS
Stroke - - - 1 - NS
Abbreviations: VT ventricular tachycardia, VF ventricular fibrillation, MACE major adverse cardiac event, PCI percutaneous coronary intervention, TVR target vessel
revascularization, TLR target lesion revascularization, MI myocardial infarction, CABG coronary artery bypass graft
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[7]. A 1999 survey showed that the prevalence of dia-
betes in China was about 9%, and increased to 11.6% as
of 2010 [1]. The overall proportion of those with acute
coronary syndrome (ACS) in youth patients (including
unstable angina, STEMI and NSTEMI) increased; with
an especially notable rises in the proportion of unstable
angina. This may be associated with increased risk fac-
tors for young CHD, which underscores the need for
secondary prevention.
The present study shows that from 2010 to 2014 fast-
ing blood glucose levels and glycosylated hemoglobin
declined slightly without statistical difference, and the
incidence of diabetes increased from 20.3 to 26.1%; far
from optimistic figures. Hyperlipidemia increased signifi-
cantly; results from national research in 2010 showed
that total cholesterol levels were ≥6.22 mmol/L for men
and women, with prevalence of 3.2 and 3.4%, respect-
ively. The results of the present study showed that from
2010 to 2014, the incidence of hyperlipidemia in young
CHD patients increased from 27.3 to 35.7%, while the
percentage of patients receiving statin therapy is still
<80%. This study also found that BMI shows an increas-
ing trend, while obesity and being overweight are also
potential risk factors for CHD. Here we also found that
CRP decreased from 2010 to 2014, which may be associ-
ated with a decrease of the proportion of myocardial in-
farction as shown in another report [8].
The report of cardiovascular disease in China in 2014
shows that the proportion of overweight urban and rural
residents is about 30%, with obesity is at 12%. These are
potentially susceptible populations for CHD. BMI
showed a significantly increasing trend in young CHD
patients. Obesity can promote proliferation of vascular
endothelial cells and activation of inflammatory re-
sponse, which are associated with endothelial dysfunc-
tion and atherosclerosis [9–11]. Obesity can also lead to
accelerated vascular aging, and increased risk of athero-
sclerotic disease [12–15]. Smoking is associated with
blood lipid disturbance, inflammation, and vascular
endothelial dysfunction [16–18]. Smoking has been con-
sidered one of the main risk factors for CHD among
young people [19]. The present study further showed
that, despite the declines in smoking and drinking, the
overall proportions for both are still high, and the aver-
age incidences exceed 50 and 25%, respectively. Analysis
of laboratory test results showed that total cholesterol
and triglyceride levels showed a downward trend, while
LDL cholesterol did not change significantly. This is as-
sociated with lack of exercise, obesity, and other lifestyle
choices, as also shown in both the Coronary Artery Risk
Development in Young Adults Study and Cardiovascular
Risk in Young Finns Study [20, 21]. A large number of
studies proved statins could reduce the incidence of car-
diovascular events and inhibit development of coronary
plaque [22]. However, the present study showed that in
the hospital, <80% of young CHD patients received sta-
tin therapy. We also found the proportion presented
with upstream trend, which was partly due to lack of
exercise.
The olderly patients presented with multiple, diffuse,
and calcification lesions, while young CHD patients pre-
sented with acute onset, less collateral circulation, and
more total occlusive disease [23]. The present study
showed that young CHD patients presented with single
branch lesions, mainly in the LAD, followed by RCA,
and LCx. As per ACC/AHA classification [24], this study
showed the incidence of simple type A lesions had re-
duced, while the complex type C lesions increased over
the course of the examined years. The events in-
hospital, overall mortality, and cardiogenic shock
trended downward trend, and major bleeding, malignant
ventricular arrhythmia, and acute or subacute thrombus
demonstrated no difference. This may be partly associ-
ated with improvements in medical and interventional
treatments. No significant improvement in MACE, in-
cluding cardiac death, myocardial infarction, CABG,
PCI, and stroke incidence, was found after 1 year.
Conclusions
Ultimately, this study confirmed that from 2010 to
2014, with updated guidelines applied in clinical treat-
ment, secondary prevention has gradually been pro-
moted. However, many shortcomings are still seen,
such as the rising incidence of hypertension, diabetes,
hyperlipidemia, and higher BMI. The ratio of smokers
is still high. In medical treatment, use of aspirin, clopi-
dogrel, statins, and ß-blockers have improved overall,
but the control of heart rate and blood lipids levels are
still low. A great deal of progress is still needed for
young patients regarding primary and secondary pre-
vention of CHD, including BMI control, smoking cessa-
tion, rehabilitation exercise, and reducing hypertension,
diabetes and hyperlipidemia.
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